骨髓增生异常综合征当前挑战与未满足的医疗需求
本文综述骨髓增生异常综合征(MDS)的异质性、贫血负担及治疗困境:低危患者缺乏明确标准治疗,高危患者现有治疗多非治愈且易复发耐药,分子诊断进展提示需个体化策略。
要点
- MDS异质性强,多数患者伴贫血及贫血相关症状,影响生活质量。
- 低危MDS现有治疗下许多患者仍无明确标准治疗。
- 高危MDS治疗目标为延缓进展至急性髓系白血病并改善总生存。
核心结论
- MDS现有治疗总体非治愈,许多患者复发或对一线治疗耐药,亟需更有效且可耐受的新策略。
- MDS驱动基因异常多样,要求复杂且个体化的治疗 approach。
研究设计与样本
- 本文为综述,讨论当前MDS治疗格局的挑战及在研新方法。
主要发现
- MDS为异质性髓系肿瘤,特征为无效造血、血细胞减少程度不一及进展为急性髓系白血病的风险。
- 多数MDS患者受贫血及贫血相关症状影响,生活质量下降。
- 许多低危MDS患者接受现有治疗管理,但当前无明确标准治疗。
- 高危MDS治疗优先改变疾病自然史,即延迟进展至急性髓系白血病并改善总生存。
- 现有MDS治疗一般非治愈,许多患者出现复发或对一线治疗耐药。
临床怎么用
- 低危MDS应结合贫血及症状管理,但需认识到许多患者缺乏明确标准治疗。
- 高危MDS治疗决策以延迟进展至急性髓系白血病和改善总生存为核心目标。
- 分子诊断进展提示应依据基因异常多样性考虑个体化治疗策略。
局限性
- 本文为综述,未报告原始研究样本量、疗效数值或统计比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of progression to acute myeloid leukemia. Most patients with MDS are affected by anemia and anemia-related symptoms, which negatively impact their quality of life. While many patients with MDS have lower-risk disease and are managed by existing treatments, there currently is no clear standard of care for many patients. For patients with higher-risk disease, the treatment priority is changing the natural history of the disease by delaying disease progression to acute myeloid leukemia and improving overall survival. However, existing treatments for MDS are generally not curative and many patients experience relapse or resistance to first-line treatment. Thus, there remains an unmet need for new, more effective but tolerable strategies to manage MDS. Recent advances in molecular diagnostics have improved our understanding of the pathogenesis of MDS, and it is becoming clear that the diverse nature of genetic abnormalities that drive MDS demands a complex and personalized treatment approach. This review will discuss some of the challenges related to the current MDS treatment landscape, as well as new approaches currently in development.
引用
- Platzbecker U, Kubasch AS, Homer-Bouthiette C, et al. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021. PMID: 34045662. doi:10.1038/s41375-021-01265-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。